Home › Companies › Arcus Biosciences, Inc. › 2024-2025

Arcus Biosciences, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
210Asset managers
1,623Fund votes
June 10, 2025Meeting date

Results at a glance

Meeting of June 10, 2025: 6 items on Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025: 6 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Arcus Biosciences, Inc.

These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcus Biosciences, Inc. — official shareholder meeting results, meeting held June 10, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Yasunori Kaneko, M.D.	86,171,508	--	--	4,142,191	8,580,999	95%	Not verified	—
Elect Director: Patrick Machado, J.D.	72,358,392	--	--	17,955,307	8,580,999	80%	Not verified	—
Elect Director: Andrew Perlman, M.D., Ph.D	84,672,810	--	--	5,640,889	8,580,999	94%	Not verified	—
Elect Director: Antoni Ribas, M.D., Ph.D.	74,827,393	--	--	15,486,306	8,580,999	83%	Not verified	—
2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025	96,750,327	1,952,359	192,012	--	--	98%	Not verified	—
3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement	84,812,809	5,446,383	54,507	--	8,580,999	94%	Not verified	—

Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.

How asset managers voted at the Arcus Biosciences, Inc. 2024-2025 meeting

Each item below shows how the 210 asset managers that disclosed a Arcus Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Andrew Perlman, M.D., Ph.D

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 84,672,810WITHHELD: 5,640,889

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Directors: Andrew Perlman, M.D., Ph.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Andrew Perlman, M.D., Ph.D”): 84,672,810 for, 5,640,889 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 23,481,581 for, 1,160,752 withheld, 11 abstained.

FOR

FOR: 23,481,581ABSTAIN: 11WITHHOLD: 1,160,752

Largest asset managers voting on “Election of Directors: Andrew Perlman, M.D., Ph.D.” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
BlackRock	6,842,859	0	0	For
Vanguard	6,561,971	11	0	For
Fidelity	5,682,656	0	0	For
State Street	1,275,371	0	527	For
Dimensional	0	0	993,030	Withhold
Charles Schwab	651,485	0	0	For
Delaware/Macquarie	379,100	0	0	For
Victory Capital	169,107	0	0	For
Equitable	88,160	0	58,500	Mixed
Columbia Threadneedle	142,961	0	0	For
Jackson National	115,043	0	20,859	Mixed
TIAA	129,930	0	0	For
American Century	105,381	0	0	For
QUANTITATIVE MASTER SERIES LLC	95,512	0	0	For
MFS	78,952	0	0	For
ALPS ETF Trust	77,040	0	0	For
Prudential/PGIM	60,673	0	14,180	Mixed
BNY Mellon	71,161	0	0	For
Principal	65,361	0	0	For
Direxion Shares ETF Trust	59,317	0	0	For
Empower	53,707	0	0	For
Exchange Place Advisors Trust	49,977	0	0	For
Thrivent	49,429	0	0	For
Lincoln Financial	40,300	0	7,101	Mixed
Goldman Sachs	46,686	0	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

2. Elect Director: Antoni Ribas, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD

FOR: 74,827,393WITHHELD: 15,486,306

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Directors: Antoni Ribas, M.D., Ph.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Antoni Ribas, M.D., Ph.D.”): 74,827,393 for, 15,486,306 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 20,707,914 for, 3,934,409 withheld, 21 abstained.

FORWITHHOLD

FOR: 20,707,914ABSTAIN: 21WITHHOLD: 3,934,409

Largest asset managers voting on “Election of Directors: Antoni Ribas, M.D., Ph.D.” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
BlackRock	6,842,859	0	0	For
Vanguard	6,561,961	21	0	For
Fidelity	5,677,425	0	5,231	For
State Street	3,309	0	1,272,589	Withhold
Dimensional	0	0	993,030	Withhold
Charles Schwab	651,485	0	0	For
Delaware/Macquarie	0	0	379,100	Withhold
Victory Capital	0	0	169,107	Withhold
Equitable	88,160	0	58,500	Mixed
Columbia Threadneedle	0	0	142,961	Withhold
Jackson National	115,043	0	20,859	Mixed
TIAA	129,930	0	0	For
American Century	0	0	105,381	Withhold
QUANTITATIVE MASTER SERIES LLC	95,512	0	0	For
MFS	0	0	78,952	Withhold
ALPS ETF Trust	0	0	77,040	Withhold
Prudential/PGIM	60,673	0	14,180	Mixed
BNY Mellon	71,161	0	0	For
Principal	0	0	65,361	Withhold
Direxion Shares ETF Trust	0	0	59,317	Withhold
Empower	0	0	53,707	Withhold
Exchange Place Advisors Trust	49,977	0	0	For
Thrivent	0	0	49,429	Withhold
Lincoln Financial	0	0	47,401	Withhold
Goldman Sachs	46,686	0	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

3. Elect Director: Patrick Machado, J.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD

FOR: 72,358,392WITHHELD: 17,955,307

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Directors: Patrick Machado, J.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Patrick Machado, J.D.”): 72,358,392 for, 17,955,307 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 20,023,416 for, 4,618,905 withheld, 23 abstained.

FORWITHHOLD

FOR: 20,023,416ABSTAIN: 23WITHHOLD: 4,618,905

Largest asset managers voting on “Election of Directors: Patrick Machado, J.D.” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
BlackRock	6,436,892	0	405,967	Mixed
Vanguard	6,558,120	23	3,838	For
Fidelity	5,667,675	0	14,981	For
State Street	3,309	0	1,272,589	Withhold
Dimensional	0	0	993,030	Withhold
Charles Schwab	651,485	0	0	For
Delaware/Macquarie	0	0	379,100	Withhold
Victory Capital	0	0	169,107	Withhold
Equitable	88,160	0	58,500	Mixed
Columbia Threadneedle	142,961	0	0	For
Jackson National	0	0	135,902	Withhold
TIAA	129,930	0	0	For
American Century	0	0	105,381	Withhold
QUANTITATIVE MASTER SERIES LLC	95,512	0	0	For
MFS	0	0	78,952	Withhold
ALPS ETF Trust	0	0	77,040	Withhold
Prudential/PGIM	60,673	0	14,180	Mixed
BNY Mellon	0	0	71,161	Withhold
Principal	0	0	65,361	Withhold
Direxion Shares ETF Trust	0	0	59,317	Withhold
Empower	0	0	53,707	Withhold
Exchange Place Advisors Trust	49,977	0	0	For
Thrivent	0	0	49,429	Withhold
Lincoln Financial	0	0	47,401	Withhold
Goldman Sachs	0	0	46,686	Withhold

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

4. Elect Director: Yasunori Kaneko, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 86,171,508WITHHELD: 4,142,191

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: Election of Directors: Yasunori Kaneko, M.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Yasunori Kaneko, M.D.”): 86,171,508 for, 4,142,191 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 23,481,221 for, 1,161,116 withheld, 7 abstained.

FOR

FOR: 23,481,221ABSTAIN: 7WITHHOLD: 1,161,116

Largest asset managers voting on “Election of Directors: Yasunori Kaneko, M.D.” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
BlackRock	6,842,859	0	0	For
Vanguard	6,561,975	7	0	For
Fidelity	5,682,656	0	0	For
State Street	1,275,371	0	527	For
Dimensional	0	0	993,030	Withhold
Charles Schwab	651,485	0	0	For
Delaware/Macquarie	379,100	0	0	For
Victory Capital	169,107	0	0	For
Equitable	88,160	0	58,500	Mixed
Columbia Threadneedle	142,961	0	0	For
Jackson National	115,043	0	20,859	Mixed
TIAA	129,930	0	0	For
American Century	105,381	0	0	For
QUANTITATIVE MASTER SERIES LLC	95,512	0	0	For
MFS	78,952	0	0	For
ALPS ETF Trust	77,040	0	0	For
Prudential/PGIM	60,673	0	14,180	Mixed
BNY Mellon	71,161	0	0	For
Principal	65,361	0	0	For
Direxion Shares ETF Trust	59,317	0	0	For
Empower	53,707	0	0	For
Exchange Place Advisors Trust	49,977	0	0	For
Thrivent	49,429	0	0	For
Lincoln Financial	40,300	0	7,101	Mixed
Goldman Sachs	46,686	0	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

5. 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 84,812,809AGAINST: 5,446,383

Details: description as filed, official tally, votes by 210 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Arcus Biosciences, Inc.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 84,812,809 for, 5,446,383 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 71 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	6,842,859	0	For
Vanguard	6,558,133	3,849	For
Fidelity	5,682,656	0	For
State Street	1,275,286	612	For
Dimensional	993,030	0	For
Charles Schwab	651,485	0	For
Delaware/Macquarie	379,100	0	For
Victory Capital	169,107	0	For
Equitable	146,660	0	For
Columbia Threadneedle	142,961	0	For
Jackson National	135,902	0	For
TIAA	0	129,930	Against
American Century	105,381	0	For
QUANTITATIVE MASTER SERIES LLC	95,512	0	For
MFS	78,952	0	For
ALPS ETF Trust	77,040	0	For
Prudential/PGIM	14,180	60,673	Mixed
BNY Mellon	71,161	0	For
Principal	65,361	0	For
Direxion Shares ETF Trust	59,317	0	For
Empower	53,707	0	For
Exchange Place Advisors Trust	49,977	0	For
Thrivent	49,429	0	For
Lincoln Financial	47,401	0	For
Goldman Sachs	46,686	0	For

Fund voting reports, all 71 managers: 24,385,294 for, 245,795 against, 11,254 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 165 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Against	Vote
GILEAD SCIENCES, INC.	31,424,760	0	For
Woodline Partners LP	6,292,618	0	For
Fidelity	4,421,482	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	3,398,503	0	For
State Street	2,443,134	22,859	For
Point72	2,081,016	0	For
BlackRock	1,952,836	14,443	For
Siren, L.L.C.	0	0	Not Voted
GEODE CAPITAL MANAGEMENT, LLC	1,409,668	0	For
BNP Paribas Asset Management Holding S.A.	0	1,396,275	Against
RA CAPITAL MANAGEMENT, L.P.	1,029,400	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	744,301	0	For
Charles Schwab	741,231	0	For
DAFNA Capital Management LLC	627,626	0	For
Sofinnova Investments, Inc.	503,101	0	For
Wellington	472,544	0	For
MELLON INVESTMENTS Corp	384,924	0	For
Northern Trust	382,230	459	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	379,100	0	For
PRINCIPAL GLOBAL INVESTORS	336,085	0	For
Granahan Investment Management, LLC	308,320	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	281,869	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	255,064	Against
AXA INVESTMENT MANAGERS UK Ltd	0	231,608	Against
PUBLIC SECTOR PENSION INVESTMENT BOARD	229,124	0	For

Institutional-manager reports, all 165 managers: 62,603,305 for, 3,032,532 against, 575 abstained, 1,612,077 not voted. Showing the 25 largest; see all in the interactive database.

6. 2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 96,750,327AGAINST: 1,952,359

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

Arcus Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 96,750,327 for, 1,952,359 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 23,819,064 for, 812,026 against, 11,254 abstained.

FOR

FOR: 23,819,064AGAINST: 812,026ABSTAIN: 11,254

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at Arcus Biosciences, Inc., 2024-2025
Asset manager	For	Against	Vote
BlackRock	6,842,859	0	For
Vanguard	6,558,140	3,842	For
Fidelity	5,682,656	0	For
State Street	1,275,813	85	For
Dimensional	993,030	0	For
Charles Schwab	0	651,485	Against
Delaware/Macquarie	379,100	0	For
Victory Capital	169,107	0	For
Equitable	146,660	0	For
Columbia Threadneedle	142,961	0	For
Jackson National	135,902	0	For
TIAA	129,930	0	For
American Century	105,381	0	For
QUANTITATIVE MASTER SERIES LLC	95,512	0	For
MFS	78,952	0	For
ALPS ETF Trust	77,040	0	For
Prudential/PGIM	74,853	0	For
BNY Mellon	71,161	0	For
Principal	65,361	0	For
Direxion Shares ETF Trust	59,317	0	For
Empower	53,707	0	For
Exchange Place Advisors Trust	0	49,977	Against
Thrivent	49,429	0	For
Lincoln Financial	47,401	0	For
Goldman Sachs	46,686	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

Largest Arcus Biosciences, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 105,900,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	6.46%
2	Vanguard	6.20%
3	Fidelity	5.37%
4	State Street	1.20%
5	Dimensional	0.94%
6	Charles Schwab	0.62%
7	Delaware/Macquarie	0.36%
8	Victory Capital	0.16%
9	Equitable	0.14%
10	Columbia Threadneedle	0.13%

Institutional-manager reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2024-2025
#	Asset manager	% of shares outstanding
1	GILEAD SCIENCES, INC.	29.67%
2	Woodline Partners LP	5.94%
3	Fidelity	4.18%
4	SUVRETTA CAPITAL MANAGEMENT, LLC	3.21%
5	State Street	2.33%
6	Point72	1.97%
7	BlackRock	1.86%
8	Siren, L.L.C.	1.52%
9	GEODE CAPITAL MANAGEMENT, LLC	1.33%
10	BNP Paribas Asset Management Holding S.A.	1.32%

Reported Arcus Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Arcus Biosciences, Inc. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
GILEAD SCIENCES, INC.	29.67%	13D
BlackRock, Inc.	12.03%	13G
The Vanguard Group, Inc.	5.82%	DEF14A
FMR (Fidelity)	4.21%	13F
State Street	3.49%	13F
Terry Rosen, Ph.D.	2.43%	DEF14A
Dimensional Fund Advisors	1.63%	13F
Juan Carlos Jaen, Ph.D.	1.36%	DEF14A
Geode Capital	1.31%	13F
Wellington Management	1.02%	13F

Percentages above are of 105,900,000 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Arcus Biosciences, Inc.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 210 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,623 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.

Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.